Fairmount Funds Management LLC Acadia Pharmaceuticals Inc Transaction History

Fairmount Funds Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $5.27 Million - $11 Million	-405,013 Reduced 35.01%	751,804 $10.6 Million
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $15.5 Million - $20.4 Million	740,000 Added 177.54%	1,156,817 $28 Million
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $110,460 - $173,390	-7,000 Reduced 1.65%	416,817 $6.92 Million
Q2 2021 Aug 13, 2021	SELL	$19.4 - $27.42 $164,900 - $233,070	-8,500 Reduced 1.97%	423,817 $10.3 Million
Q1 2021 May 14, 2021	SELL	$25.02 - $54.99 $450,360 - $989,820	-18,000 Reduced 4.0%	432,317 $11.2 Million
Q4 2020 Feb 12, 2021	SELL	$41.04 - $56.79 $8.11 Million - $11.2 Million	-197,516 Reduced 30.49%	450,317 $24.1 Million
Q3 2020 Nov 12, 2020	BUY	$36.42 - $57.0 $2.27 Million - $3.55 Million	62,316 Added 10.64%	647,833 $26.7 Million
Q2 2020 Aug 04, 2020	SELL	$39.26 - $52.73 $706,680 - $949,140	-18,000 Reduced 2.98%	585,517 $28.4 Million
Q1 2020 May 08, 2020	BUY	$31.65 - $46.87 $2.78 Million - $4.11 Million	87,729 Added 17.01%	603,517 $25.5 Million
Q4 2019 Feb 12, 2020	BUY	$36.21 - $51.4 $18.7 Million - $26.5 Million	515,788 New	515,788 $22.1 Million

316

164M

855K

350K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.23B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.